Literature DB >> 3653222

A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.

N S Khurmi1, E B Raftery.   

Abstract

The effects of nine calcium ion antagonists on exercise tolerance, heart rate and ST-segment changes were compared with those of propranolol in two hundred and eighty patients with established chronic stable angina pectoris. These patients participated in clinical trials for anti-anginal efficacy against placebo, using identical methods and similar protocols, but the comparison reported here was retrospective. The trials were all fixed dose, and the dose was determined by previous upward titration to arrive at an average maximal tolerance level. All the drugs except prenylamine increased the exercise tolerance significantly when compared with placebo. Maximal ST-segment depression on exercise was reduced during treatment with propranolol while treatment with the calcium ion antagonists had no significant effect. The time to the development of 1 mm ST-segment depression was prolonged by all the drugs. Nifedipine, PY-108-068 and nicardipine increased the resting heart rate whereas verapamil, diltiazem, gallopamil, KB-944, prenylamine and tiapamil produced a slight reduction. Propranolol produced a highly significant reduction in the resting and maximal heart rates and the rate-pressure product, whereas gallopamil increased the rate-pressure product by +8% and prenylamine reduced it by -10%. At the doses used, diltiazem, gallopamil and verapamil produced a greater increase in exercise tolerance than did propranolol, while the other drugs were inferior. None of the calcium ion antagonists matched the increase in the time taken to develop 1 mm ST-segment depression with propranolol, although the results with verapamil and gallopamil were close. The calcium ion antagonists are effective antianginal agents which produce their effects by mechanisms which are very different to the beta-adrenoreceptor blocking agents.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3653222     DOI: 10.1007/BF02455985

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  39 in total

1.  Letter: Grading of angina pectoris.

Authors:  L Campeau
Journal:  Circulation       Date:  1976-09       Impact factor: 29.690

Review 2.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

3.  Multicenter trial of propranolol in angina pectoris.

Authors:  R H Grant; P Keelan; R J Kernohan; J C Leonard; L Nancekievill; K Sinclair
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

4.  Drugs and the heart. III. Calcium antagonists.

Authors:  L H Opie
Journal:  Lancet       Date:  1980-04-12       Impact factor: 79.321

5.  Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.

Authors:  G Ellrodt; C Y Chew; B N Singh
Journal:  Circulation       Date:  1980-10       Impact factor: 29.690

6.  Nifedipine in the treatment of Prinzmetal's (variant) angina.

Authors:  S Goldberg; N Reichek; J Wilson; J W Hirshfeld; J Muller; J A Kastor
Journal:  Am J Cardiol       Date:  1979-10-22       Impact factor: 2.778

Review 7.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

8.  Verapamil versus placebo in relieving stable angina pectoris.

Authors:  M B Pine; P D Citron; D J Bailly; S Butman; G O Plasencia; D W Landa; R K Wong
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

9.  The 24-hour ambulatory blood pressure profile with verapamil.

Authors:  B A Gould; S Mann; H Kieso; V B Subramanian; E B Raftery
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

10.  Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem.

Authors:  R P Hof
Journal:  Br J Pharmacol       Date:  1983-02       Impact factor: 8.739

View more
  4 in total

1.  Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters.

Authors:  B Silke; S de la Motte; P Spiers; N A Herity; M Drake; J Kelly; F J Harrison
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

Review 2.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 3.  Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 4.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.